Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Medical application of brain and heart beneficial tablets in treatment of Alzheimer's disease

A technology for Alzheimer's disease and heart tablets, applied in the field of medicine, can solve the problems of "Linaoxin tablets" that have not been reported in relevant literature for the prevention and treatment of Alzheimer's disease, and achieve the prevention and treatment of Alzheimer's disease. Symptoms and diseases, the effect of obvious medical effects

Inactive Publication Date: 2018-10-19
JILIN UNIV
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, there is no relevant literature report on the prevention and treatment of "Linaoxin Tablets" in Alzheimer's disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medical application of brain and heart beneficial tablets in treatment of Alzheimer's disease
  • Medical application of brain and heart beneficial tablets in treatment of Alzheimer's disease
  • Medical application of brain and heart beneficial tablets in treatment of Alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] experimental method:

[0019] Set up a soundproof obscura, the bottom area is 30 cm x 30 cm, the central area is 15 cm x 15 cm, and the rest is used as the surrounding area. On the day of testing, the mice were placed in a fixed position in the box, and their movement trajectories and the time spent exploring the central area within 5 min were observed and recorded.

[0020] Experimental results:

[0021] The mice in the blank group preferred the surrounding areas and rarely entered the central area. Compared with the blank group mice, the mice in the model group had chaotic trajectories, and the time in the central area increased significantly, while the time in the four-week area decreased significantly. After 4 weeks of administration of Linaoxin, the exercise time of the mice in the four-week area was significantly longer than that of the model group (see figure 1 ).

Embodiment 2

[0023] experimental method:

[0024] Training period: During training, the mice were put into the platform box to adapt to it for 5 minutes, and an alternating current was passed through the electric rod at the bottom, and the animal received an electric shock. The normal reaction was to jump on the platform to avoid the noxious stimulus. If the animal did not jump off the platform during the training period, it was discarded.

[0025] Test period: 24 hours after the end of the training period, put the mouse on the platform again, observe for 5 minutes, and record the time required for the animal to jump off the platform for the first time, which is the platform jumping latency.

[0026] Experimental results:

[0027] During the training period, the mice in each group would jump off the platform within 5 minutes. During the test on the second day, most of the mice in the blank group stayed on the platform within 5 minutes, while most of the mice in the model group jumped off ...

Embodiment 3

[0029] experimental method:

[0030] Training period: Put a little food on the edge of the C wall of the Y maze. After 12 hours of food deprivation, the mice are put into the Y maze from the A wall, adapt to it for 5 minutes, observe how the mice find the food, and conduct a formal test after 3 days of training. .

[0031] Test period: still put a little food on the edge of the C wall of the Y maze where the mice were deprived of food. After 12 hours of deprivation, the mice were put into the Y maze from the A wall, and the time when the mice found the food for the first time was observed.

[0032] Experimental results:

[0033] During the training period, there was no significant difference in the time for the mice in each group to find food. After 3 days of training, the time for the mice in the blank group to find food was gradually shortened, while the time for the mice in the model group to find food was significantly longer than that in the blank group. Compared with t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides medical application of brain and heart beneficial tablets in treatment of Alzheimer's disease, and has the outstanding medical treatment effect. A mice is feed with a brain andheart beneficial tablet water solution, the brain and heart beneficial tablets are proved to have the efficacy of preventing and treating Alzheimer's disease through behavioral experiments (mine test,jump platform test, Y maze test and water maze test), immunohistochemical,serum and cortical brain ELISA measuring and western blot, forming of Abeta plaque in the brain can be reduced, and the pathologic condition of Alzheimer's disease can be improved by adjusting the oxidative stress and cholinergic system.

Description

Technical field: [0001] The present invention relates to the new medical application of "Linaoxin Tablet", and further discloses the medical application of "Linaoxin Tablet" in the treatment of Alzheimer's disease, especially in the prevention and treatment of Alzheimer's disease , belonging to the field of medical technology. Background technique: [0002] Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by a marked decline in cognitive function. So far, the impact of AD is rapidly expanding globally, with more than 40 million reported patients worldwide and expected to increase to 70 million by 2030. Therefore, the prevention and treatment of AD is a serious challenge. Clinical trials of AD drugs have a high failure rate, and most of them exhibit various adverse reactions, including loss of appetite, gastrointestinal discomfort, diarrhea, vomiting, difficulty sleeping, and muscle cramps. [0003] The "Linaoxin Tablet" of the present inv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/9066A61P25/28A61K35/62
CPCA61K35/62A61K36/21A61K36/236A61K36/286A61K36/484A61K36/488A61K36/537A61K36/65A61K36/69A61K36/704A61K36/71A61K36/725A61K36/815A61K36/884A61K36/9066A61P25/28A61K2300/00
Inventor 王迪王春月初秋博滕利荣逯家辉孟庆繁徐雯雯
Owner JILIN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com